

**Supplemental content for
Utility of ^{18}F -Fluciclovine PET/MRI for Staging Newly Diagnosed High-Risk
Prostate Cancer and Evaluating Response to Initial Androgen Deprivation
Therapy: A Prospective Single-Arm Pilot Study**

*Samuel J. Galgano, MD, Andrew M. McDonald, MD, MS, Soroush Rais-Bahrami, MD,
Kristin K. Porter, MD, PhD, Gagandeep Choudhary, MD, Constantine Burgan, MD,
Pradeep Bhambhani, MD, Jeffrey W. Nix, MD, Desiree E. Morgan, MD, Yufeng Li, PhD,
John V. Thomas, MD, Jonathan McConathy, MD, PhD*

doi.org/10.2214/AJR.20.24509

Published online: October 14, 2020

The authors have supplied these materials to give readers additional information about the work.

			MR3	3	R apex-base	1	3	0	0	0	0	0	0	0	0	0	0	0	0	
10	11.1	4+5	MR1	3	mid PM PZ	1	0	0	0	0	0	1	2	0	0	0	0	0	0	
			MR2	3	L mid PZ	0	2	0	0	0	2	1	1	0	0	0	0	0	0	
			MR3	3	L mid-base	0	0	0	0	0	2	0	1	0	0	0	0	0	0	
11	36.8	4+3	MR1	3	L ant apex-base	1	1	0	0	0	0	0	0	0	0	1	1	0	0	
			MR2	3	entire gland	1	2	0	0	0	0	0	0	0	0	1	1	0	0	
			MR3	3	entire gland	1	3	0	0	0	0	0	0	0	0	2	2	0	0	
12	10.4	4+5	MR1	3	L ant CG	2	0	0	0	0	0	0	0	0	0	0	0	0	0	
			MR2	2	L apex CG	0	2	0	0	0	0	0	0	0	0	0	0	0	0	
			MR3	3	L apex-mid CG	1	0	0	0	0	0	0	0	0	0	0	0	0	0	
13	26.4	4+4	MR1	3	R base PL	2	0	0	0	0	0	2	0	0	0	0	0	0	2	R iliac
			MR2	3	R base-mid	0	1	0	0	0	0	2	0	1	1	0	0	0	0	
			MR3	3	R base-mid	0	0	0	0	1	1	3	0	1	1	0	0	0	0	
14	9.3	4+4	MR1	3	multifocal	2	0	1	0	0	0	1	0	0	0	1	0	0	0	
			MR2	3	apex-base R	2	0	0	0	0	0	0	0	1	0	1	0	0	0	
			MR3	1	R base	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
15	19.3	4+4	MR1	3	R PM apex-mid	3	0	0	0	0	0	0	0	3	0	0	0	2	0	
			MR2	3	R apex	0	0	0	0	0	0	0	0	3	0	0	0	0	0	
			MR3	3	R apex	0	0	0	0	0	0	0	0	3	0	0	0	0	0	

PSA=prostate specific antigen. PCa=prostate cancer. EPE=extraprostatic extension. SVI=seminal vesicle invasion. RCI=right common iliac. LM=lymph node. LCI=left common iliac. RII=right internal iliac. LII=left internal iliac. REI=right external iliac. LEI=left external iliac. RO=right obturator. LO=left obturator. RI=right inguinal. LI=left inguinal. PAo=paraaortic. B=base. PZ=peripheral zone. R=right. L=left. Ant=anterior. PL=posterolateral. PM=posteromedial. CG=central gland. Hetero=heterogeneous. Fem=femoral.

Table S2: Patient data and individual ¹⁸F-fluciclovine PET/MRI reads for pretreatment PET/MRI.*

Study #	PSA	Gleason	Reader	PCa Likert score (0-3)	Location	EPE	SVI	RCI LN	LCI LN	RII LN	LII LN	REI LN	LEI LN	RO LN	LO LN	RI LN	LI LN	PAo LN	Skeletal	Location	Extrapelvic Distant Met	Location	
1	76.5	4+5	PT1	3	diffuse	1	3	0	0	3	3	0	0	0	0	0	0	0	0		0		
			PT2	3	diffuse	0	3	0	0	3	3	0	0	0	0	0	0	0	0	0		0	
			PT3	3	diffuse	0	3	0	0	3	3	1	1	0	0	1	1	0	0	0		0	
2	12.9	4+4	PT1	3	R post	2	2	0	0	0	0	0	0	0	0	0	0	0	0		0		
			PT2	3	R base	0	3	0	0	0	0	0	0	0	0	0	0	0	0	0		0	
			PT3	3	R PZ	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0		0	
3	8.4	4+5	PT1	3	L	3	0	0	0	0	0	0	0	0	0	0	0	0	0		0		
			PT2	3	peripheral L	3	0	0	0	0	0	0	0	0	0	0	0	0	0	3	R frontal	0	
			PT3	3	L PZ	3	0	0	0	0	0	0	0	0	0	1	1	0	0	0		0	
4	51.4	3+4	PT1	1	diffuse	0	0	2	3	0	0	0	0	0	0	0	0	0	0		2	RP LN	
			PT2	3	base	0	0	0	3	0	0	0	0	0	0	0	0	0	0	0		2	RP LN
			PT3	3	R PZ	0	0	0	2	0	0	2	0	0	0	1	1	0	0	0		2	RP LN
5	17.6	4+4	PT1	3	diffuse	2	0	0	0	0	0	0	0	0	0	0	0	0	0		0		
			PT2	3	diffuse	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		0	
			PT3	3	diffuse	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0		0	
6	57.7	3+4	PT1	3	diffuse	0	3	0	0	0	0	0	0	0	0	0	0	0	0		0		
			PT2	3	diffuse	0	3	0	0	0	0	3	0	0	0	1	1	0	0	0		0	
			PT3	3	diffuse	0	2	0	0	2	0	2	0	0	1	1	1	0	0	0		0	
7	2.8	4+5	PT1	3	R post	1	0	0	0	0	0	0	0	0	0	0	0	0	0		3	RP LN	
			PT2	3	bilateral	0	0	0	0	0	0	1	0	0	0	1	1	0	0	0		3	RP LN
			PT3	3	R PZ	0	0	0	0	0	0	2	0	0	0	1	1	0	0	0		2	RP LN
8	100.0	4+3	PT1	3	R ant L post	3	0	1	0	0	0	0	0	0	0	0	0	0	0		0		
			PT2	3	bilateral	3	3	0	0	0	0	0	0	0	0	0	0	0	0	0		0	
			PT3	3	R apex, L	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0		0	
9	30.9	4+3	PT1	3	diffuse	2	0	0	0	0	0	0	0	0	0	0	0	0	0		0		
			PT2	2	periph R	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0		0	
			PT3	3	B apex PZ	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0		0	

10	11.1	4+5	PT1	3	R post	1	2	0	3	0	0	3	3	0	0	0	0	0	0	0	0		0	
			PT2	3	bilobar	0	0	0	2	0	0	3	3	0	0	0	0	0	0	0	0		0	
			PT3	3	bilateral	0	0	0	3	0	0	3	3	0	3	1	1	0	0	0	0		0	
11	36.8	4+3	PT1	3	diffuse	3	3	0	0	0	0	0	0	0	0	0	0	0	0	0	0		0	
			PT2	3	diffuse	3	0	0	0	0	0	0	2	0	0	1	1	0	0	0	0		0	
			PT3	3	diffuse	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0		0	
12	10.4	4+5	PT1	3	diffuse	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		0	
			PT2	3	L apex	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		0	
			PT3	3	L PZ	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0		0	
13	26.4	4+4	PT1	3	central and R peripheral	3	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0		0	
			PT2	3	R periph and bilat base	0	0	0	0	0	0	3	2	0	0	1	1	0	0	0	0		0	
			PT3	3	diffuse	0	0	0	0	0	0	3	2	0	1	1	1	0	0	0	0		0	
15	9.3	4+4	PT1	3	R apex	0	0	0	0	0	0	0	0	3	0	1	1	3	0	0	0		3	L ischiorectal fossa
			PT2	3	R apex	0	0	0	0	0	0	0	0	3	0	0	0	3	0	0	0		3	L ischiorectal fossa
			PT3	3	R apex	0	0	0	0	0	0	0	0	3	0	1	1	3	0	0	0		3	L ischiorectal fossa

Patient 14 excluded due to lost images.

PSA=prostate specific antigen. PCa=prostate cancer. EPE=extraprostatic extension. SVI=seminal vesicle invasion. RCI=right common iliac. LM=lymph node. LCI=left common iliac. RII=right internal iliac. LII=left internal iliac. REI=right external iliac. LEI=left external iliac. RO=right obturator. LO=left obturator. RI=right inguinal. LI=left inguinal. PAo=paraaortic. B=base. PZ=peripheral zone. R=right. L=left. Ant=anterior. PL=posterolateral. PM=posteromedial. CG=central gland. Hetero=heterogeneous. Fem=femoral.

10	0.3	PATIENT UNABLE TO COMPLETE ENTIRE EXAM AND NO DEDICATED PROSTATE MRI PERFORMED																	
11	1.3	MR1	3	diffuse	2	2	0	0	0	0	0	0	0	0	0	0	0	0	0
		MR2	2	diffuse	2	2	0	0	0	0	0	0	0	0	0	0	0	0	0
		MR3	2	L mid and base	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
12	<0.1	MR1	prostatectomy	NA	NA	NA	0	0	0	0	1	0	0	0	0	0	0	0	0
		MR2	prostatectomy	NA	NA	NA	0	0	0	0	0	0	0	0	0	0	0	0	0
		MR3	prostatectomy	NA	NA	NA	0	0	0	0	0	0	0	0	0	0	0	0	1
13	1.1	MR1	2	R apex-mid and L apex	2	0	0	0	0	0	2	1	0	0	1	1	0	0	0
		MR2	2	R apex-base	0	1	0	0	0	0	2	0	0	0	0	0	0	0	0
		MR3	3	R mid	2	0	0	0	0	0	3	0	0	0	0	0	0	0	0
15	5.7	MR1	3	R apex	3	0	0	0	0	0	2	0	2	0	0	0	0	0	0
		MR2	3	R apex	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		MR3	3	R mid	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0

Patient 14 excluded due to lost images.

PSA=prostate specific antigen. PCa=prostate cancer. EPE=extraprostatic extension. SVI=seminal vesicle invasion. RCI=right common iliac. LM=lymph node. LCI=left common iliac. RII=right internal iliac. LII=left internal iliac. REI=right external iliac. LEI=left external iliac. RO=right obturator. LO=left obturator. RI=right inguinal. LI=left inguinal. PAo=para-aortic. B=base. PZ=peripheral zone. R=right. L=left. Ant=anterior. PL=posterolateral. PM=posteromedial. CG=central gland. Hetero=heterogeneous. Fem=femoral.

Table S4: Patient data and individual ¹⁸F-fluciclovine PET/MRI reads for posttreatment PET/MRI.

Study #	PSA	Reader	PCa Likert score (0-3)	Location	EPE	SVI	RCI LN	LCI LN	RII LN	LII LN	REI LN	LEI LN	RO LN	LO LN	RI LN	LI LN	PAo LN	Skeletal	Location	Extrapelvic/ Distant Met	Location	
1	5.45	PT1	0	NA	0	0	0	0	0	0	0	0	0	0	1	1	0	0		0		
		PT2	3	midline near apex	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0		0	
		PT3	0	NA	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		0	
2	<0.1 0	PT1	prostatectomy	NA	NA	NA	0	0	0	0	0	0	0	0	0	0	0	0		0		
		PT2	prostatectomy	NA	NA	NA	0	0	0	0	0	0	0	0	0	1	1	0	0		0	
		PT3	prostatectomy	NA	NA	NA	0	0	0	0	0	0	0	0	0	0	0	0	0		0	
3	<0.1 0	WITHDREW																				
4	0.45	PT1	0	NA	0	0	0	0	0	0	2	3	0	0	1	3	0	0		0		
		PT2	3	bilateral	0	0	0	0	0	0	1	3	0	0	1	1	0	0		0		
		PT3	2	diffuse	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		0	
5	1.45	PT1	1	diffuse	0	0	0	0	0	0	1	0	0	0	1	1	0	2	S2	0		
		PT2	3	bilateral	0	0	0	0	0	0	0	0	0	0	1	1	0	0		1		
		PT3	2	diffuse	0	0	0	0	0	0	0	0	0	0	0	0	0	0		0		
6	0.81	PT1	3	diffuse	0	0	0	0	3	0	1	0	0	0	1	1	0	0		0		
		PT2	3	bilateral	0	0	0	0	2	0	0	0	0	0	1	1	0	0		0		
		PT3	2	diffuse	0	0	0	0	0	0	1	0	0	0	0	0	0	0		0		
7	0.99	PT1	0	NA	0	0	0	0	0	0	0	0	0	0	1	1	0	0		3	RP LN	
		PT2	3	R apex	3	3	0	0	0	0	1	0	0	0	1	1	0	0		0		
		PT3	1	R PZ	0	0	0	0	0	0	0	0	0	0	0	0	0	0		2	RP LN	
8		LOST TO FOLLOW-UP																				
9	3.8	PT1	2	R lateral	0	0	0	0	0	0	0	0	0	0	1	1	0	0		0		
		PT2	3	R	0	0	0	0	0	0	1	0	0	0	1	1	0	0		0		
		PT3	2	R	0	0	0	0	0	0	0	0	0	0	0	0	0	0		0		

10	0.29	PT1	3	L peripheral	0	0	0	0	0	0	0	0	0	0	3	1	1	0	0		0	
		PT2	3	bilateral	3	3	0	0	0	0	1	0	0	0	2	1	1	0	0		1	
		PT3	2	L PZ	1	1	0	0	0	0	0	0	0	0	2	0	0	0	0		0	
11	1.32	PT1	0	NA	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		0	
		PT2	2	L peripheral	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0		0	
		PT3	0	NA	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		0	
12	0.01	PT1	prostatectomy	NA	NA	NA	0	0	0	0	0	0	0	0	0	1	1	0	0		0	
		PT2	prostatectomy	NA	NA	NA	0	0	0	0	1	0	0	0	0	1	1	0	0		0	
		PT3	prostatectomy	NA	NA	NA	0	0	0	0	0	0	0	0	0	0	0	0	0		0	
13	1.08	PT1	3	diffuse	0	0	0	0	0	0	2	2	0	0	1	1	0	0		0		
		PT2	3	bilateral	0	0	0	0	0	0	3	2	0	0	1	1	0	0		0		
		PT3	2	diffuse	0	0	0	0	0	0	3	3	0	0	0	0	0	0		0		
15	5.66	PT1	2	central	0	0	0	0	0	0	0	0	0	0	1	1	0	0		0		
		PT2	3	bilateral central	0	0	0	0	0	0	0	0	0	0	1	1	0	0		0		
		PT3	2	central	0	0	0	0	0	0	0	0	0	0	0	0	0	0		0		

Patient 14 excluded due to lost images.

PSA=prostate specific antigen. PCa=prostate cancer. EPE=extraprostatic extension. SVI=seminal vesicle invasion. RCI=right common iliac. LM=lymph node. LCI=left common iliac. RII=right internal iliac. LII=left internal iliac. REI=right external iliac. LEI=left external iliac. RO=right obturator. LO=left obturator. RI=right inguinal. LI=left inguinal. PAo=paraaortic. B=base. PZ=peripheral zone. R=right. L=left. Ant=anterior. PL=posterolateral. PM=posteromedial. CG=central gland. Hetero=heterogeneous. Fem=femoral.